eligibility_summary
Men and women with multiple myeloma or plasmacytoma aiming for strict complete remission, expected survival >12 weeks, prior auto-SCT allowed regardless of other therapies. Must have adequate venous access with no contraindications to leukapheresis and provide informed consent and follow-up. Excludes pregnant/lactating, uncontrolled infection, active HIV/HBV/HCV, systemic steroid use (inhaled OK), or other medical conditions that preclude participation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Combination autologous CAR-T cell therapy (adoptive cellular immunotherapy, biological) targeting BCMA and GPRC5D. Mechanism of action: Patient T cells are engineered to express chimeric antigen receptors that bind BCMA (TNFRSF17, a TNF-receptor family protein on plasma cells) and GPRC5D (a GPCR highly expressed on plasma cells), activating T-cell cytotoxicity to eliminate malignant plasma cells, dual targeting aims to reduce antigen escape and enhance efficacy/persistence. Cells/pathways targeted: Plasma cells in high-risk multiple myeloma/plasmacytoma expressing BCMA and/or GPRC5D, immune effector T-cell activation against these antigens.